MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF), a biotechnology company specializing in AI-driven voice technology for intoxication detection, announced it has filed patent applications for its technology that uses voice and artificial intelligence to detect drug and alcohol intoxication. The company’s Edge AI Intoxication Detection Kiosks analyze the human voice using over 50 million data points to predict intoxication levels, and commercial testing hardware and software solutions for the mining and aviation industries are on track for delivery by the end of Q2 2026.
This development marks a significant step in workplace safety, particularly for high-risk industries such as mining, aviation, construction, and law enforcement. The ability to quickly and non-invasively detect impairment could reduce accidents, save lives, and lower costs associated with workplace incidents. For the mining industry, where heavy machinery operation requires alertness, voice-based screening offers a faster alternative to traditional breathalyzers or blood tests. Similarly, in aviation, ensuring pilots are fit to fly is critical for passenger safety.
The patent filings protect MindBio’s proprietary AI prediction model, which uses over 50 million data points to assess alcohol intoxication with high accuracy. According to the company, the technology can predict alcohol intoxication just by analyzing the human voice. This approach could revolutionize how companies conduct drug and alcohol testing, moving from invasive and time-consuming methods to a simple voice sample.
MindBio is developing an enterprise platform that includes Edge-AI kiosks integrating bespoke hardware and software. These kiosks are designed for deployment in various enterprise environments. The company’s focus on the mining and aviation industries underscores the potential for widespread adoption in sectors where impairment poses severe risks.
For investors, this announcement signals MindBio’s progress in commercializing its technology. The patent applications strengthen the company’s intellectual property portfolio and could provide a competitive advantage in the growing market for workplace safety solutions. As regulatory scrutiny around workplace impairment increases, technologies like MindBio’s may become more essential. The company’s timeline for delivery by Q2 2026 suggests that commercial products are within reach, potentially opening new revenue streams.
For more information, visit the company’s newsroom at https://nnw.fm/MBQIF.
